...
首页> 外文期刊>Medical principles and practice: international journal of the Kuwait University, Health Science Centre >The role of CYP2C9 gene polymorphisms on anticoagulant therapy after heart valve replacement.
【24h】

The role of CYP2C9 gene polymorphisms on anticoagulant therapy after heart valve replacement.

机译:CYP2C9基因多态性在心脏瓣膜置换术后抗凝治疗中的作用。

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

OBJECTIVE: The aim of the present study was to investigate the role of CYP2C9 gene polymorphisms after heart valve replacement in a group of patients on warfarin therapy. MATERIALS AND METHODS: The study population consisted of 74 patients with heart valve replacement. Peripheral blood was collected into evacuated tubes containing EDTA, and DNA was extracted from circulating leukocytes by using a high pure PCR template preparation kit. CYP2C9*2, CYP2C9*3 alleles were detected by using real-time PCR. RESULTS: The patients with CYP2C9*1/*3 and CYP2C9*2/*3 genotypes were taking 28.21 and 24.47 mg, respectively, as mean weekly warfarin dose, whereas patients with CYP2C9*1/*1 genotype were taking 33.90 mg. CONCLUSION: The data show that patients with CYP2C9*1/*3 and CYP2C9*2/*3 genotypes needed a lower maintenance dose of warfarin than patients with CYP2C9*1/*1 wild-type genotype.
机译:目的:研究CYP2C9基因多态性在华法林治疗组患者心脏瓣膜置换术后的作用。材料与方法:研究人群包括74例心脏瓣膜置换术患者。将外周血收集到装有EDTA的真空管中,并使用高纯度PCR模板制备试剂盒从循环白细胞中提取DNA。通过实时PCR检测CYP2C9 * 2,CYP2C9 * 3等位基因。结果:CYP2C9 * 1 / * 3和CYP2C9 * 2 / * 3基因型的患者平均每周华法林剂量分别为28.21和24.47 mg,而CYP2C9 * 1 / * 1基因型的患者每周平均华法林剂量为33.90 mg。结论:数据显示CYP2C9 * 1 / * 3和CYP2C9 * 2 / * 3基因型患者的华法林维持剂量低于CYP2C9 * 1 / * 1野生型患者。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号